Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development

Cytometry Part B - Clinical Cytometry

Volumn 90, Issue 2, 2016, Pages 117-127

  Liang, Meina ^a   Schwickart, Martin ^a   Schneider, Amy K ^a   Vainshtein, Inna ^a   Del Nagro, Christopher ^a   Standifer, Nathan ^a   Roskos, Lorin K ^a  

^a MEDIMMUNE   (United States)

Author keywords

animal and human studies; biopharmaceutical; clinical trial; dose selection; drug development; flow cytometry; pharmacodynamic biomarker; PKPD relationship; receptor occupancy; target binding

Indexed keywords

BIOLOGICAL MARKER; REAGENT;

ASSAY; BINDING AFFINITY; BLOOD SAMPLING; CELL SURFACE; DRUG DEVELOPMENT; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; INFORMATION PROCESSING; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; PHARMACOKINETICS; PROCEDURES;

BIOMARKERS; DRUG DISCOVERY; FLOW CYTOMETRY; HUMANS; PHARMACOKINETICS;

EID: 84962162143     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21259     Document Type: Review

References (66)

1. Hrusovsky K., Getting on the critical path: better evaluation tools for drug discovery and development. Drug Discov Today 2006; 11: 773-774.
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
3. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
4. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, et al., Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009; 27: 5800-5807.
5. Hua F, Comer GM, Stockert L, Jin B, Nowak J, Pleasic-Williams S, Wunderlich D, Cheng J, Beebe JS., Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 2014; 54: 14-22.
6. Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B, Schreiber S, Mansfield JC, Williams M, Tang M, et al., A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut 2013; 62: 1122-1130.
7. FDA. Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. FDA; 2005. URL http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf
8. EMA. Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. EMA; 2007. URL http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002988.pdf
9. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA, et al., Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1785-1796.
10. Bissonnette R, Papp K, Maari C, Yao Y, Robbie G, White WI, Le C, White B., A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol 2010; 62: 427-436.
11. Macdougall IC., Optimizing the use of erythropoietic agents-pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002; 17: 66-70. Suppl 5:-.
12. Johnson M., Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006; 117: 18-24. quiz 25.
13. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, et al., Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11: 1170-1172.
14. Abraham AK, Kagan L, Kumar S, Mager DE., Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice. J Pharmacol Exp Ther 2010; 334: 327-332.
15. Agoram BM., Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics. Br J Clin Pharmacol 2009; 67: 153-160.
16. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N., Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-1028.
17. Lowe PJ, Hijazi Y, Luttringer O, Yin H, Sarangapani R, Howard D., On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica 2007; 37: 1331-1354.
18. Muller PY, Brennan FR., Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin Pharmacol Ther 2009; 85: 247-258.
19. FDA. Guidance for industry S6 preclinical safety evaluation of biotechnology-derived pharmaceuticals. FDA; 1997. URL http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074957.pdf
20. Ma A, Dun H, Song L, Hu Y, Zeng L, Bai J, Zhang G, Kinugasa F, Miyao Y, Sakuma S, et al., Pharmacokinetics and pharmacodynamics of ASKP1240, a fully human anti-CD40 antibody, in normal and renal transplanted Cynomolgus monkeys. Transplantation 2014; 97: 397-404.
21. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak M, Jagannath S, et al., Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008; 26: 3196-3203.
22. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175.
23. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, et al., Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: A phase 2b randomised dose-ranging study. Lancet Respir Med 2014; 2: 879-890.
24. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, et al., IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
25. Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall'Acqua W, Tedder T, Kiener P, Coyle AJ, Wu H, et al., A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 2011; 155: 426-437.
26. Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K, DiPersio J., A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1253-1261.
27. Rothman RB, Yang HY, Long JB., Upregulation of rat brain opioid receptors by the chronic administration of morphine: Possible evidence for an anti-opiate model of tolerance and dependence. NIDA Res Monogr 1990; 105: 264-270.
28. Brodowicz T, Wiltschke C, Budinsky AC, Krainer M, Steger GG, Zielinski CC., Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer 1997; 73: 875-879.
29. Roskos LK, Schneider A, Vainshtein I, Schwickart M, Lee R, Lu H, Faggioni R, Liang M., PK-PD modeling of protein drugs: Implications in assay development. Bioanalysis 2011; 3: 659-675.
30. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T., Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-3964.
31. Mutsaers AJ, Francia G, Man S, Lee CR, Ebos JM, Wu Y, Witte L, Berry S, Moore M, Kerbel RS., Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clin Cancer Res 2009; 15: 2397-2405.
32. Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Schirripa M, Di Desidero T, Antoniotti C, Canu B, et al., EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Target Oncol 2014; 9: 205-214.
33. Wang B, Lau YY, Liang M, Vainshtein I, Zusmanovich M, Lu H, Magrini F, Sleeman M, Roskos L., Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis. J Clin Pharmacol 2012; 52: 1150 -11 61.
34. Heinzelmann M, Polk HC Jr., Chernobelsky A, Stites TP, Gordon LE., Endotoxin and muramyl dipeptide modulate surface receptor expression on human mononuclear cells. Immunopharmacology 2000; 48: 117-128.
35. Willmann K, Dunne JF., A flow cytometric immune function assay for human peripheral blood dendritic cells. J Leukoc Biol 2000; 67: 536-544.
36. Freeman DJ, McDorman K, Ogbagabriel S, Kozlosky C, Yang BB, Doshi S, Perez-Ruxio JJ, Fanslow W, Starnes C, Radinsky R., Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Mol Cancer 2012; 11: 47
37. Chattopadhyay PK, Gaylord B, Palmer A, Jiang N, Raven MA, Lewis G, Reuter MA, Nur-ur Rahman AK, Price DA, Betts MR, et al., Brilliant violet fluorophores: A new class of ultrabright fluorescent compounds for immunofluorescence experiments. Cytometry Part A 2012; 81A: 456-466.
38. Dall'Acqua WF, Kiener PA, Wu H., Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281: 23514-23524.
39. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al., Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006; 103: 4005 -40 10.
40. Oganesyan V, Gao C, Shirinian L, Wu H, Dall'Acqua WF., Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr 2008; 64: 700-704.
41. Davis C, Wu X, Li W, Fan H, Reddy M., Stability of immunophenotypic markers in fixed peripheral blood for extended analysis using flow cytometry. J Immunol Methods 2011; 363: 158-165.
42. Warrino DE, DeGennaro LJ, Hanson M, Swindells S, Pirruccello SJ, Ryan WL., Stabilization of white blood cells and immunologic markers for extended analysis using flow cytometry. J Immunol Methods 2005; 305: 107-119.
43. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, Halk E, Goldstein J, Schuurman J, van Dijk MA, et al., Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004; 173: 4699-4707.
44. Verbon A, Dekkers PE, ten Hove T, Hack CE, Pribble JP, Turner T, Souza S, Axtelle T, Hoek FJ, van Deventer SJ., and others. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001; 166: 3599-605.
45. Logue EC, Bakkour S, Murphy MM, Nolla H, Sha WC., ICOS-induced B7h shedding on B cells is inhibited by TLR7/8 and TLR9. J Immunol 2006; 177: 2356-2364.
46. Green CL, Brown L, Stewart JJ, Xu Y, Litwin V, Mc Closkey TW., Recommendations for the validation of flow cytometric testing during drug development: I instrumentation. J Immunol Methods 2011; 363: 104-119.
47. Maecker HT, Trotter J., Flow cytometry controls, instrument setup, and the determination of positivity. Cytometry Part A 2006; 69A: 1037-1042.
48. Chan LY, Yim EK, Choo AB., Normalized median fluorescence: An alternative flow cytometry analysis method for tracking human embryonic stem cell states during differentiation. Tissue Eng Part C Methods 2013; 19: 156-165.
49. Pan WJ, Kock K, Rees WA, Sullivan BA, Evangelista CM, Yen M, Andrews JM, Radford-Smith GL, Prince PJ, Reynhardt KO, et al., Clinical pharmacology of AMG 181, a gut-specific human anti-alpha beta monoclonal antibody, for treating inflammatory bowel diseases. Br J Clin Pharmacol 2014; 78: 1315-1333.
50. O'Hara DM, Xu Y, Liang Z, Reddy MP, Wu DY, Litwin V., Recommendations for the validation of flow cytometric testing during drug development: II assays. J Immunol Methods 2011; 363: 120-134.
51. Cedeno-Arias M, Sanchez-Ramirez J, Blanco-Santana R, Rengifo-Calzado E., Validation of a flow cytometry based binding assay for evaluation of monoclonal antibody recognizing EGF receptor. Sci Pharm 2011; 79: 569-581.
52. Bergeron M, Shafaie A, Ding T, Phaneuf S, Soucy N, Mandy F, Bradley J, Fahey J., Evaluation of stabilized blood cell products as candidate preparations for quality assessment programs for CD4 T-cell counting. Cytometry 2002; 50: 86-91.
53. Ding T, Bergeron M, Seely P, Yang X, Diallo TO, Plews M, Sandstrom P, Ball TB, Meyers AF., Compatibility of stabilized whole blood products with CD4 technologies and their suitability for quality assessment programs. PLoS One 2014; 9: e103391
54. Vainshtein I, Schneider AK, Sun B, Schwickart M, Roskos LK, Liang M,. Multiplexing of Receptor Occupancy measurements for Pharmacodynamic Biomarker Assessment of Biopharmaceuticals. Cytometry Part B, in press.
55. Streitz M, Miloud T, Kapinsky M, Reed MR, Magari R, Geissler EK, Hutchinson JA, Vogt K, Schlickeiser S, Kverneland AH, et al., Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res 2013; 2: 17.
56. Tabrizi M, Bornstein GG, Suria H., Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J 2010; 12: 33-43.
57. Jasper GA, Arun I, Venzon D, Kreitman RJ, Wayne AS, Yuan CM, Marti GE, Stetler-Stevenson M., Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin Cytom 2011; 80: 83-90.
58. Tembhare PR, Marti G, Wiestner A, Degheidy H, Farooqui M, Kreitman RJ, Jasper GA, Yuan CM, Liewehr D, Venzon D, et al., Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia. Am J Clin Pathol 2013; 140: 813-883.
59. Rosario MC, Jacqmin P, Dorr P, James I, Jenkins TM, Abel S, van der Ryst E., Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients. Br J Clin Pharmacol 2008; 65 Suppl 1: 86-94.
60. Finak G, Jiang W, Krouse K, Wei C, Sanz I, Phippard D, Asare A, De Rosa SC, Self S, Gottardo R., High-throughput flow cytometry data normalization for clinical trials. Cytometry Part A 2014; 85A: 277-286.
61. Hahne F, Khodabakhshi AH, Bashashati A, Wong CJ, Gascoyne RD, Weng AP, Seyfert-Margolis V, Bourcier K, Asare A, Lumley T, et al., Per-channel basis normalization methods for flow cytometry data. Cytometry Part A 2010; 77A: 121-131.
62. Bridges EM, Bibby MC, Burchill SA., The hollow fiber assay for drug responsiveness in the Ewing's sarcoma family of tumors. J Pediatr 2006; 149: 103-111.
63. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR., In vivo cultivation of tumor cells in hollow fibers. Life Sci 1995; 57: 131-141.
64. Palframan R, Airey M, Moore A, Vugler A, Nesbitt A., Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009; 348: 36-41.
65. Zou P, Xu S, Povoski SP, Wang A, Johnson MA, Martin EW Jr., Subramaniam V, Xu R, Sun D., Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol Pharm 2009; 6: 428-440.
66. Giesen C, Wang HA, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B, Schuffler PJ, Grolimund D, Buhmann JM, Brandt S, et al., Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods 2014; 11: 417-422.